Abbott Laboratories (ABT) faced a market fall exceeding the broader indexes, yet remains a consistent dividend stock. Both, sell-offs and new investments, have been witnessed in various portfolios. An increasing interest is noted among institutional owners, holding 81% of Abbott.
Investment dynamics show a flurry of buying, selling, and increased positions by diverse financial entities like ORG Wealth Partners, Cove Private Wealth, and various others.
Expert options like Jim Cramer endorse the investment in Abbott amid worrying Covid trends. Its diagnostics arm expansion fortifies the ABT stock, despite wider economical challenges. Q3 2025 results are expected on 15th October, before market open. The received average target price from brokerages stands at $145.22.
Mixed market predictions are prevalent for future movements and Wall Street analysts are still determining the potential climb or sink status of the stock. Abbott's muted earnings remain unavoidable.
Q2 earnings are anticipated soon and are creating additional market buzz, along with a potential acquisition in Pokeno sparking fresh speculations. However, a recent rare guidance miss led to a 8% drop of Abbott Laboratories shares.
Abbott Laboratories ABT News Analytics from Wed, 09 Jul 2025 07:00:00 GMT to Sat, 27 Sep 2025 17:12:02 GMT -
Rating 3
- Innovation 1
- Information 7
- Rumor 4
